DK1479696T3 - Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi - Google Patents

Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi

Info

Publication number
DK1479696T3
DK1479696T3 DK04102692T DK04102692T DK1479696T3 DK 1479696 T3 DK1479696 T3 DK 1479696T3 DK 04102692 T DK04102692 T DK 04102692T DK 04102692 T DK04102692 T DK 04102692T DK 1479696 T3 DK1479696 T3 DK 1479696T3
Authority
DK
Denmark
Prior art keywords
binds
cam
monoclonal antibody
cancer therapy
human monoclonal
Prior art date
Application number
DK04102692T
Other languages
Danish (da)
English (en)
Inventor
Ton Dr Logtenberg
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK1479696T3 publication Critical patent/DK1479696T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK04102692T 1999-12-27 2000-12-21 Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi DK1479696T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99204561 1999-12-27
EP00991344A EP1242823B1 (de) 1999-12-27 2000-12-21 Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken
PCT/NL2000/000941 WO2001048485A2 (en) 1999-12-27 2000-12-21 Selecting library members capable of binding to epitopes

Publications (1)

Publication Number Publication Date
DK1479696T3 true DK1479696T3 (da) 2007-05-07

Family

ID=8241110

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04102692T DK1479696T3 (da) 1999-12-27 2000-12-21 Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi

Country Status (11)

Country Link
US (2) US20030096225A1 (de)
EP (3) EP1242823B1 (de)
JP (1) JP2003518391A (de)
AT (3) ATE366419T1 (de)
AU (1) AU783148B2 (de)
CA (1) CA2396029A1 (de)
DE (3) DE60038132T2 (de)
DK (1) DK1479696T3 (de)
ES (1) ES2282797T3 (de)
NZ (2) NZ531590A (de)
WO (1) WO2001048485A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1495142B1 (de) * 2002-04-17 2007-09-26 Bioren, Inc. Doping bei der walk-through-mutagenese
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2374465A1 (de) * 2003-09-08 2011-10-12 E. I. du Pont de Nemours and Company Pflegespülung auf Peptidbasis und Färbemittel für Haar, Haut und Nägel
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
CN103998932B (zh) 2011-06-29 2017-06-06 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
TWI485161B (zh) * 2012-03-02 2015-05-21 中央研究院 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
WO2015153816A2 (en) 2014-04-01 2015-10-08 Academia Sinica Methods and systems for cancer diagnosis and prognosis
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
WO2019213624A1 (en) * 2018-05-04 2019-11-07 The Regents Of The University Of California Spiked primers for enrichment of pathogen nucleic acids among background of nucleic acids
WO2021211510A2 (en) * 2020-04-13 2021-10-21 Affyimmune Therapeutics, Inc. Epcam antibody and car-t cells
WO2022126084A1 (en) * 2020-12-09 2022-06-16 Affyimmune Therapeutics, Inc. Dual chimeric antigen receptor targeting epcam and icam-1
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0934526B1 (de) * 1996-10-08 2003-01-08 U-BISys B.V. Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
US6787638B1 (en) * 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
AU3244701A (en) 2001-07-09
NZ531590A (en) 2006-01-27
ATE386747T1 (de) 2008-03-15
JP2003518391A (ja) 2003-06-10
AU783148B2 (en) 2005-09-29
DE60035434T2 (de) 2008-05-15
US20030096225A1 (en) 2003-05-22
DE60038132T2 (de) 2009-04-02
CA2396029A1 (en) 2001-07-05
ES2282797T3 (es) 2007-10-16
WO2001048485A9 (en) 2002-09-06
EP1273918B1 (de) 2008-02-20
ATE353920T1 (de) 2007-03-15
WO2001048485A3 (en) 2002-01-31
EP1242823A2 (de) 2002-09-25
DE60035434D1 (de) 2007-08-16
WO2001048485A2 (en) 2001-07-05
US20030096226A1 (en) 2003-05-22
DE60033455T2 (de) 2007-11-29
EP1273918A2 (de) 2003-01-08
EP1479696A1 (de) 2004-11-24
DE60038132D1 (de) 2008-04-03
EP1273918A3 (de) 2003-05-02
ATE366419T1 (de) 2007-07-15
EP1242823B1 (de) 2007-07-04
NZ520074A (en) 2004-04-30
DE60033455D1 (de) 2007-03-29
US7777010B2 (en) 2010-08-17
EP1479696B1 (de) 2007-02-14

Similar Documents

Publication Publication Date Title
DK1479696T3 (da) Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi
DE69433406D1 (de) Antikörper gegen cd40
DE69941598D1 (de) Anti-ccr2 antikörper sowie deren verwendung
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
DE69936927D1 (de) Polyspezifische bindemoleküle und deren verwendung
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
DK0996728T3 (da) Forbedrede anti-IgE antistoffer og fremgangsmåde til forbedring af antistoffer
DE60235588D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
ATE290879T1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
SI1572087T1 (sl) Protitelesa proti antigenu tmeff2 raka in njihovauporaba
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
DE60327072D1 (de) Spezifische antikörperfragmente für das humane carcinoembryonic antigen (cea)
DK0709455T3 (da) Monoklonalt antistof med humanglicentin, hybridoma til fremstilling af antistoffet og assaymetode for humanglicentin ved an
DK1629009T3 (da) Sammensætninger omfattende store og små bindefragmenter af antistoffer rettet imod det samme toksin
HUT75824A (en) A novel endothelial cell molecule mediating lymphocyte binding in man
AU5990100A (en) ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
ZA986064B (en) Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and their use.
BR1100582B1 (pt) famÍlia de anticorpos modificados, de alta afinidade, para tratamento de cÂncer.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk